Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
Moleculin Biotech Inc (NASDAQ: MBRX) closed the day trading at $0.51 down -27.91% from the previous closing price of $0.70. In other words, the price has decreased by -$27.91 from its previous closing price. On the day, 2.68 million shares were traded. MBRX stock price reached its highest trading level at $0.6448 during the session, while it also had its lowest trading level at $0.5.
Ratios:
For a better understanding of MBRX, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.08 and its Current Ratio is at 2.08. In the meantime, Its Debt-to-Equity ratio is 0.07 whereas as Long-Term Debt/Eq ratio is at 0.05.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MBRX now has a Market Capitalization of 1714791 and an Enterprise Value of -7491538.
Stock Price History:
The Beta on a monthly basis for MBRX is 1.96, which has changed by 0.3803922 over the last 52 weeks, in comparison to a change of 0.21313763 over the same period for the S&P500. Over the past 52 weeks, MBRX has reached a high of $10.35, while it has fallen to a 52-week low of $0.66. The 50-Day Moving Average of the stock is -72.26%, while the 200-Day Moving Average is calculated to be -82.63%.
Shares Statistics:
Over the past 3-months, MBRX traded about 94.36K shares per day on average, while over the past 10 days, MBRX traded about 262330 shares per day. A total of 3.38M shares are outstanding, with a floating share count of 3.27M. Insiders hold about 3.14% of the company’s shares, while institutions hold 13.63% stake in the company. Shares short for MBRX as of 1738281600 were 173263 with a Short Ratio of 1.80, compared to 1735603200 on 82126. Therefore, it implies a Short% of Shares Outstanding of 173263 and a Short% of Float of 5.2800003.
Earnings Estimates
The consensus estimate for the next quarter is $0, with high estimates of $0 and low estimates of $0.
Analysts are recommending an EPS of between -$14.09 and -$14.09 for the fiscal current year, implying an average EPS of -$14.09. EPS for the following year is -$5.28, with 1.0 analysts recommending between -$5.28 and -$5.28.
